Maybe it’s time to offer your patients the benefits of regenerative therapies? 

What products are effective and compliant with FDA guidelines? 

What are the best protocols? 

What are the conditions we can treat effectively? etc.

 Learn all about amnionic membranes, flowable allografts, sourcing, compliance, manufacturing, conditions treated and more...

Our manufacturer has the most innovative products and is compliant with FDA, AATB etc. BioStem presentation:

https://www.beautiful.ai/player/-MLxUfh3Y4e1ZXwPG4P6/Sales-Presentation-Main

With medical care focused on managing or delaying the progression of chronic disease and illness, the number of ailing patients throughout the United States is staggering. Many patients are caught up in a vicious cycle of seeing multiple doctors and specialists with no hope for healing in sight.

Yet, there are great developments taking shape in the form of regenerative medicine, with new innovations, techniques and therapies.

With the potential to fully heal damaged tissues and organs, regenerative medicine is awarding individuals with persistent or life-altering diseases a new lease on life. This is by targeting and treating the underlying cause of their condition, including musculoskeletal pain and injury. 

At GENOMICS, we use the most innovative amnionic membranes and flowable allografts available today. The minimally manipulated structural, human tissues are safe and effective for homologous use. The perinatal tissues are derived from the placenta and umbilical cord. Components of these tissues include (but are not limited to): growth factors, cytokines, mesenchymal stem cells, exosomes, HA (hyaluronic acid), collagens, and scaffolding. The intended use is for the repair, reconstruction, replacement, or supplementation of a recipient's cells or tissues; and to physically serve as a barrier or conduit, or connect, cover, or cushion a damaged tissue.

Perinatal tissues and allografts are much easier to apply, and research shows they contain more viable components than autografts obtained from the patient's own adipose tissue or bone marrow.

At GENOMICS,  we implement the recommendations set forth by the FDA. HCT/P's (Human Cellular Tissues and Products) are regulated solely under section 361 of the PHS Act, and regulations in 21 CFR Part 1271.

The human tissues we use are minimally manipulated and intended for homologous use only. Homologous use means the repair, reconstruction, replacement, or supplementation of a recipient’s cells or tissues with an HCT/P that performs the same basic function or functions in the recipient as in the donor.

The products we use are structural tissues that contain cells. Structural tissues physically  support or serve as a barrier or conduit, or connect, cover, or cushion. Amniotic membrane and umbilical cord are considered structural tissues.  Relevant characteristics of structural tissues include strength, flexibility, cushioning, covering, compressibility, and response to friction or shear. 

Repair means the physical or mechanical restoration of tissues, including by covering or protecting.